MODERNA INC (MRNA) Stock Fundamental Analysis

NASDAQ:MRNA • US60770K1079

39.34 USD
-1.17 (-2.89%)
Last: Feb 12, 2026, 11:57 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall MRNA gets a fundamental rating of 3 out of 10. We evaluated MRNA against 523 industry peers in the Biotechnology industry. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, MRNA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MRNA has reported negative net income.
  • MRNA had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

  • The Return On Assets of MRNA (-25.68%) is better than 71.13% of its industry peers.
  • MRNA has a better Return On Equity (-33.40%) than 73.42% of its industry peers.
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • MRNA's Gross Margin of 63.49% is fine compared to the rest of the industry. MRNA outperforms 79.16% of its industry peers.
  • In the last couple of years the Gross Margin of MRNA has declined.
  • The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRNA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MRNA has been increased compared to 5 years ago.
  • MRNA has a better debt/assets ratio than last year.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • MRNA has an Altman-Z score of 4.13. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of MRNA (4.13) is better than 70.75% of its industry peers.
  • MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of MRNA (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.13
ROIC/WACCN/A
WACC12.37%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 3.93 indicates that MRNA has no problem at all paying its short term obligations.
  • MRNA has a Current ratio of 3.93. This is comparable to the rest of the industry: MRNA outperforms 47.23% of its industry peers.
  • MRNA has a Quick Ratio of 3.73. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.73, MRNA perfoms like the industry average, outperforming 47.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.73
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for MRNA have decreased strongly by -38.66% in the last year.
  • The Revenue for MRNA has decreased by -56.07% in the past year. This is quite bad
  • The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%

3.2 Future

  • Based on estimates for the next years, MRNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.39% on average per year.
  • The Revenue is expected to grow by 10.92% on average over the next years. This is quite good.
EPS Next Y12.27%
EPS Next 2Y11.07%
EPS Next 3Y13.21%
EPS Next 5Y16.39%
Revenue Next Year-41.3%
Revenue Next 2Y-20.98%
Revenue Next 3Y-10.57%
Revenue Next 5Y10.92%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.
  • Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MRNA's earnings are expected to grow with 13.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.07%
EPS Next 3Y13.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MRNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MODERNA INC

NASDAQ:MRNA (2/12/2026, 11:57:09 AM)

39.34

-1.17 (-2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-13
Inst Owners71.72%
Inst Owner Change-2.11%
Ins Owners2.73%
Ins Owner Change1.52%
Market Cap15.37B
Revenue(TTM)2.23B
Net Income(TTM)-3.12B
Analysts56
Price Target39.68 (0.86%)
Short Float %19.39%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.94%
Min EPS beat(2)29.6%
Max EPS beat(2)76.27%
EPS beat(4)3
Avg EPS beat(4)30.21%
Min EPS beat(4)-6.26%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)49.68%
EPS beat(12)9
Avg EPS beat(12)9.25%
EPS beat(16)12
Avg EPS beat(16)10.78%
Revenue beat(2)2
Avg Revenue beat(2)17.81%
Min Revenue beat(2)12.36%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)8.94%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.87%
Revenue beat(12)10
Avg Revenue beat(12)27.21%
Revenue beat(16)13
Avg Revenue beat(16)22.97%
PT rev (1m)5.56%
PT rev (3m)-7.96%
EPS NQ rev (1m)2.86%
EPS NQ rev (3m)9.24%
EPS NY rev (1m)0.91%
EPS NY rev (3m)18.04%
Revenue NQ rev (1m)-3.18%
Revenue NQ rev (3m)-16.42%
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.89
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-8.07
EYN/A
EPS(NY)-7.11
Fwd EYN/A
FCF(TTM)-6.82
FCFYN/A
OCF(TTM)-5.06
OCFYN/A
SpS5.71
BVpS23.88
TBVpS23.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.49%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 329.33%
Cap/Sales 30.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.73
Altman-Z 4.13
F-Score2
WACC12.37%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
EPS Next Y12.27%
EPS Next 2Y11.07%
EPS Next 3Y13.21%
EPS Next 5Y16.39%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%
Revenue Next Year-41.3%
Revenue Next 2Y-20.98%
Revenue Next 3Y-10.57%
Revenue Next 5Y10.92%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.26%
EBIT Next 3Y15.27%
EBIT Next 5Y17.94%
FCF growth 1Y-0.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / MRNA FAQ

What is the fundamental rating for MRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRNA.


What is the valuation status for MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (MRNA). This can be considered as Overvalued.


How profitable is MODERNA INC (MRNA) stock?

MODERNA INC (MRNA) has a profitability rating of 2 / 10.